Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 203

1.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX.

J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.

2.

Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial.

Niska JR, Keane FK, Wolfgang JA, Hahn PF, Wo JY, Zhu AX, Hong TS.

Pract Radiat Oncol. 2016 Jan-Feb;6(1):e9-e16. doi: 10.1016/j.prro.2015.08.005. Epub 2015 Aug 28.

PMID:
26598907
3.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Dec 3;528(7580):152. doi: 10.1038/nature16136. Epub 2015 Nov 18. No abstract available.

PMID:
26580013
4.

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.

Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-Del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR.

Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.

PMID:
26373575
5.

Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

PLoS One. 2015 Sep 14;10(9):e0136725. doi: 10.1371/journal.pone.0136725. eCollection 2015.

6.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

PMID:
26245674
7.

Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

J Comput Assist Tomogr. 2015 Sep-Oct;39(5):687-96. doi: 10.1097/RCT.0000000000000288.

PMID:
26222909
8.

Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

Acad Radiol. 2015 Nov;22(11):1344-60. doi: 10.1016/j.acra.2015.05.012. Epub 2015 Jul 23.

PMID:
26211553
9.

Changes in land use, climate and the environment during a period of rapid economic development in Jiangsu Province, China.

Huang C, Zhang M, Zou J, Zhu AX, Chen X, Mi Y, Wang Y, Yang H, Li Y.

Sci Total Environ. 2015 Dec 1;536:173-81. doi: 10.1016/j.scitotenv.2015.07.014. Epub 2015 Jul 21.

PMID:
26204053
10.

An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.

Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG.

Nat Protoc. 2015 Aug;10(8):1264-74. doi: 10.1038/nprot.2015.080. Epub 2015 Jul 23.

PMID:
26203823
11.

Chemotherapy and antiangiogenics in biliary tract cancer.

Goyal L, Chong DQ, Duda DG, Zhu AX.

Lancet Oncol. 2015 Aug;16(8):882-3. doi: 10.1016/S1470-2045(15)00093-5. Epub 2015 Jul 12. No abstract available.

12.

Consensus conference on hilar cholangiocarcinoma.

Forsmark CE, Diniz AL, Zhu AX.

HPB (Oxford). 2015 Aug;17(8):666-8. doi: 10.1111/hpb.12451. No abstract available.

PMID:
26172133
13.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
14.

Future directions in the treatment of cholangiocarcinoma.

Zhu AX.

Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):355-61. doi: 10.1016/j.bpg.2015.02.010. Epub 2015 Feb 19. Review.

PMID:
25966434
15.

Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.

Sahani DV, Hayano K, Galluzzo A, Zhu AX.

AJR Am J Roentgenol. 2015 Apr;204(4):776-81. doi: 10.2214/AJR.14.13223.

PMID:
25794066
16.

Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology.

Ferrone CR, Ting DT, Shahid M, Konstantinidis IT, Sabbatino F, Goyal L, Rice-Stitt T, Mubeen A, Arora K, Bardeesy N, Miura J, Gamblin TC, Zhu AX, Borger D, Lillemoe KD, Rivera MN, Deshpande V.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:1609. doi: 10.1245/s10434-015-4510-7. No abstract available.

PMID:
25786746
17.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N.

Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00173-4. doi: 10.1016/j.celrep.2015.02.027. [Epub ahead of print]

18.

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.

Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D, Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D, Zhu AX, Schlegel R, Huang A.

Mol Cancer Ther. 2015 May;14(5):1224-35. doi: 10.1158/1535-7163.MCT-14-0768. Epub 2015 Feb 27.

PMID:
25724664
19.

Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.

Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S.

J Vasc Interv Radiol. 2015 Apr;26(4):516-22. doi: 10.1016/j.jvir.2014.12.020. Epub 2015 Feb 18.

PMID:
25704226
20.

Self-catalysed aerobic oxidization of organic linker in porous crystal for on-demand regulation of sorption behaviours.

Liao PQ, Zhu AX, Zhang WX, Zhang JP, Chen XM.

Nat Commun. 2015 Feb 23;6:6350. doi: 10.1038/ncomms7350.

PMID:
25702689
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk